Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial — Live Feedhttps://www.live-feeds.com/feed/eli-lilly-says-closely-watched-combo-obesity-regimen-boosts-weight-loss-in-mid-stage-trialContinuously updated, source-cited coverage. Eli Lilly combo drug EloraTZP beats tirzepatide in mid-stage trialhttps://www.live-feeds.com/feed/eli-lilly-says-closely-watched-combo-obesity-regimen-boosts-weight-loss-in-mid-stage-trialhttps://www.live-feeds.com/feed/eli-lilly-says-closely-watched-combo-obesity-regimen-boosts-weight-loss-in-mid-stage-trial#u100925Mon, 05 Oct 2026 02:05:58 +0000Eli Lilly reported that EloraTZP, a combination of tirzepatide and the experimental amylin drug eloralintide, outperformed tirzepatide 15 mg in a 48-week Phase 2 trial. The study involved adults with obesity and type 2 diabetes, showing that patients lost an average of 23.3% of their body weight and saw improved A1C reduction compared to tirzepatide alone. Following these positive results, the company intends to launch Phase 3 trials for the combination regimen by the end of 2026.Why it mattersThe obesity market is highly competitive, with Eli Lilly and Novo Nordisk facing new challenges from